Author: Omar, Alaa Z.; Mosa, Tawfik M.; El-sadany, Samer K.; Hamed, Ezzat A.; El-atawy, Mohamed
Title: Novel piperazine based compounds as potential inhibitors for SARS-CoV-2 Protease Enzyme: Synthesis and molecular docking study Cord-id: va03u9tf Document date: 2021_12_5
ID: va03u9tf
Snippet: Structurally diverse piperazine-based compounds hybrid with thiadiazole, isatin or with sulfur/nitrogen, functionalities were synthesized. The structures of the new compounds were established based on their spectral data and elemental analysis. The physicochemical, bioactivity scores and pharmacokinetic behavior of all the prepared ligands were evaluated using in silico computational tools. The new piperazine ligands have been screened for their inhibition activity against SARS-CoV-2 protease en
Document: Structurally diverse piperazine-based compounds hybrid with thiadiazole, isatin or with sulfur/nitrogen, functionalities were synthesized. The structures of the new compounds were established based on their spectral data and elemental analysis. The physicochemical, bioactivity scores and pharmacokinetic behavior of all the prepared ligands were evaluated using in silico computational tools. The new piperazine ligands have been screened for their inhibition activity against SARS-CoV-2 protease enzyme using molecular docking analysis. The docking studies showed that all the ligands have been docked with negative dock energy onto the target protease protein. Moreover, Molecular interaction studies revealed that SARS-CoV-2 protease enzyme had strong hydrogen bonding interactions with piperazine ligands. The present in silico study thus, provided some guidance to facilitate drug design targeting the SARS-CoV-2 main protease.
Search related documents:
Co phrase search for related documents- acetic acid and active compound: 1
- acetic acid and active site: 1, 2
- active compound and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- active compound and acute toxicity: 1, 2, 3, 4, 5
- active compound and low acute toxicity: 1
- active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- active site and acute toxicity: 1
- active site and adme property: 1
- active site and low acute toxicity: 1
- active site and low protease: 1
- active site residue and acute respiratory syndrome: 1, 2
- acute respiratory syndrome and adme property: 1, 2, 3, 4, 5
- acute respiratory syndrome and liver normal function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory syndrome and low acute toxicity: 1, 2
- acute respiratory syndrome and low protease: 1, 2, 3, 4, 5, 6
- acute toxicity and low acute toxicity: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date